Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 17, 2021
As the GFF wraps up its sixth year of operations, enters its next strategic period, and undertakes an important replenishment campaign to raise an additional $2.5 billion in trust fund resources, we are excited to share new work on the role of the GFF in improving the impact of health spending for R...
POLICY PAPERS
December 17, 2021
The Global Financing Facility (GFF), launched in 2015, is a partnership backed by a multi-donor World Bank trust fund that aims to “prioritize and scale-up evidence-driven investments to improve reproductive, maternal, newborn, child, and adolescent health and nutrition (RMNCAH-N) interventions” in ...
CGD NOTES
August 11, 2021
Over the past two decades, partnerships between bilateral and multilateral funders, philanthropy, national governments, and the private sector have substantially increased global access to effective malaria treatment. Nevertheless, further action on malaria case management is needed to meet global t...
Blog Post
May 17, 2021
Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and...
WORKING PAPERS
December 14, 2020
Between 2011 and 2016, the Affordable Medicines Facility-Malaria (AMFm) subsidy program substantially increased access to WHO prequalified artemisinin combination therapies (ACTs) through Africa’s private sector pharmacies and drug-sellers. While the program was rigorously and extensively evaluated,...
Blog Post
November 09, 2020
This morning, America (and much of the world) woke up to a snippet of terrific news: Pfizer and BioNTech announced their SARS-CoV2 vaccine candidate showed 90 percent efficacy. But for policymakers in low- and middle-income countries, today’s news offers limited cause for celebration—and the Pfizer/...